examlife.info’s Post

World Antimicrobial Resistance Awareness Week, from November 18-24 is commencing today. Antimicrobial Resistance is a silent pandemic and it is claiming millions of lives every year. According to a report published in 2014 under the supervision of Jim O'Neil, a British economist, that AMR could claim 10 million lives every year and cost the economy US $100 trillion by 2050. The theme for this year is, "Educate. Advocate. Act Now". Play your part by simply raising awareness against antimicrobial resistance. Major reasons for exacerbating antibiotic resistance trends are inappropriate and indiscriminate use of antibiotics, improper prescription, unregulated use of antibiotics in agriculture and poultry industry as growth factors. Lack of investments and funding in developing new antibiotics is also a concerning issue. More than 150 antibiotics have been developed and resistance against the majority of the antibiotics have been reported. Avoid taking antibiotics without the prescription of the doctor. In case your doctor prescribed you antibiotics, please complete the drugs regimen. If you feel that your health condition is improving then don't discontinue the medications during your treatment.

🌍 Tackling Antimicrobial Resistance (AMR): A Historic Breakthrough from India! It feel proud to announce the launch of Nafithromycin (trade name: Miqnaf), India’s first indigenously developed antibiotic aimed at combating the global health crisis of Antimicrobial Resistance (AMR). This innovation represents a monumental achievement in the field of biotechnology and healthcare, made possible through the support of the Biotechnology Industry Research Assistance Council (BIRAC) under the Department of Biotechnology (DBT) and the dedicated efforts of Wockhardt Ltd. Nafithromycin offers a revolutionary solution to Community-Acquired Bacterial Pneumonia (CABP)—a severe condition caused by drug-resistant pathogens that disproportionately affects vulnerable populations like children, the elderly, and immune-compromised individuals. Nafithromycin is a novel lactone ketolide antibiotic, acting on 50s ribosomal subunit. With a three-day regimen, it is 10x more effective than existing treatments like azithromycin, with superior safety, tolerability, and minimal side effects. This groundbreaking antibiotic is the first of its class to be developed globally in over three decades, showcasing India’s scientific and technological advancement. It addresses both typical and atypical pathogens, overcoming existing resistance mechanisms. With 23% of the global pneumonia burden falling on India, this innovation is a much-needed game-changer #InnovationInHealthcare #AMR #AntimicrobialResistance #Nafithromycin #MakeInIndia #Biotechnology #PublicPrivatePartnership #CABP #GlobalHealth #ResearchAndDevelopment #BIRAC

The IFPMA report titled "From Resistance to Resilience: What Could the Future Antibiotic Pipeline Look Like?" addresses the growing concern of antibiotic resistance and the inadequacy of the current antibiotic pipeline to combat this issue. Key Takeaways: - Antimicrobial Resistance (AMR) Impact: AMR is directly responsible for 1.2 million deaths annually worldwide and is associated with approximately 5 million deaths. - Economic Model Necessity: There is a pressing need to establish a long-term economic model that offers end-to-end sustainability on a global basis for antibiotic R&D. - Incentive Introduction: Effective incentives could lead to the approval of new antibiotics, which are expected to significantly reduce the Disability Adjusted Life Years (DALY) burden by more than 50% compared to having no new antibiotics. To further study the findings, please refer to the attached report.

India’s First Indigenous Antibiotic Launched! India has introduced Nafithromycin, a novel ketolide antibiotic to combat drug-resistant infections like Community-Acquired Bacterial Pneumonia (CABP). Developed with BIRAC’s support, it’s 10x more effective, safer, and highly tolerable, marking a significant leap in the fight against Antimicrobial Resistance (AMR). A proud moment for Indian innovation and global health! #HealthcareInnovation #AMR #Biotechnology

Global antibiotic consumption has increased by more than 21 percent since 2016: new studies shows a decrease in consumption in high-income countries has been countered by an increase in middle-income countries.

Self-medication with antibiotics further aggravates antibiotic resistance... and there is a real fear of therapeutic impasses for MDR infections in the coming years...

Only 10 new antibiotics or combinations were approved between 2017 and 2023, only two of which are defined as innovative by the World Health Organisation.                                                                                None are considered to constitute a new class of antibiotics.                                     Learn more about what the future antibiotic pipeline could look like in the new IFPMA report: https://shorturl.at/ivAlr #AMR #Antibiotics #ResearchAndDevelopment

Antibiotic resistance poses a challenging threat to global public health, as evidenced by its direct responsibility for 1.3 million deaths in 2019. The overuse of broad-spectrum antibiotics in healthcare settings, particularly in developing countries, is fueling the emergence of multi-drug resistant strains. The Middle East and North Africa (MENA) region, too, experienced a parallel escalation in antibiotic usage during the pandemic. The unique challenges faced by healthcare systems in this region, coupled with the increased prevalence of antibiotic prescriptions, amplify the risk of identifying multi-drug resistant strains. Check out our latest report "Bridging the Bacterial Resistance Gap" through the below link #Antibioticresistance #Drugresistance #Superbug #AMR #Treatmentfailure #antibiotic #antimicrobialresistance #Superbugs #Stories_of_AMR #AMRAwareness #fightAMR #Antibiotics #Innovation #Drugdevelopment #AI

The Indian School of Business (ISB) Indian School of Business Hyderabad invited us to participate in a round table discussion on November 20, 2024. The topic of discussion was developing sustainable pathways for introducing new reserve antibiotics 💊 in India, with particular emphasis on linking stewardship with access to ensure responsible use and minimize resistance development. ⚡ highlights of the meeting 🤝 🔴 Need for Sustainable Pathways: The growing threat of antimicrobial resistance (AMR) necessitates the development of sustainable pathways for introducing new reserve antibiotics in India. 🔴Linking Stewardship with Access: Ensuring responsible use and minimizing resistance development requires linking antibiotic stewardship with access to these medicines . 🔴 National Action Plan: India's National Action Plan on AMR aims to combat antimicrobial resistance, but there is a need for greater focus on drug procurement, access, and rational use. 🔴 Regulations and Surveillance: Implementing regulations for antibiotic use and misuse, along with national surveillance, is crucial for monitoring AMR and promoting responsible use. 🔴Access to Essential Antibiotics: Ensuring access to essential antibiotics is critical, particularly in low-resource settings. ➡️ WHO's AWARE System: The World Health Organization's (WHO) Access, Watch, Reserve (AWARE) system can help define, monitor, and evaluate appropriate levels of antibiotic use and access.